Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
Sejung Hwang,1 Dae Young Lee,2 Joo-Youn Cho,1,3 Jae-Yong Chung,4 In-Jin Jang,1 Kyung-Sang Yu,1,3 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Drug Metabolism and Pharmacokinetics (DMPK), D...
Main Authors: | Hwang S, Lee DY, Cho JY, Chung JY, Jang IJ, Yu KS, Lee S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-06-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/pharmacokinetics-tolerability-and-pharmacogenetics-of-da-8031-after-mu-peer-reviewed-fulltext-article-DDDT |
Similar Items
-
Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
by: Shin D, et al.
Published: (2017-03-01) -
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
by: Kim S, et al.
Published: (2017-11-01) -
A pharmacodynamic model of the role of 5-HT2A and GABAA receptors in the delay in the onset of action of SSRIS
by: Chan, Patrick G.
Published: (2009) -
Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
by: Thanh Thanh L. Nguyen, et al.
Published: (2021-01-01) -
Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
by: Azmeraw T. Amare, et al.
Published: (2018-03-01)